147 related articles for article (PubMed ID: 32170479)
1. ASO Author Reflections: Defining Oligometastatic Recurrence in Biliary Tract Cancer.
Morino K; Yoh T; Seo S
Ann Surg Oncol; 2020 Jun; 27(6):1918. PubMed ID: 32170479
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: Role of Local Treatment for Oligometastatic Esophagogastric Cancer.
Kroese TE; van Rossum PSN; van Hillegersberg R
Ann Surg Oncol; 2022 Aug; 29(8):4858-4860. PubMed ID: 35307806
[No Abstract] [Full Text] [Related]
3. Proposed Definition for Oligometastatic Recurrence in Biliary Tract Cancer Based on Results of Locoregional Treatment: A Propensity-Score-Stratified Analysis.
Morino K; Seo S; Yoh T; Fukumitsu K; Ishii T; Taura K; Morita S; Kaido T; Uemoto S
Ann Surg Oncol; 2020 Jun; 27(6):1908-1917. PubMed ID: 31939034
[TBL] [Abstract][Full Text] [Related]
4. ASO Author Reflections: Tumor Location Affects Local Recurrence in Rectal Cancer.
Franz C; Kulu Y
Ann Surg Oncol; 2020 Feb; 27(2):439. PubMed ID: 31673942
[No Abstract] [Full Text] [Related]
5. ASO Author Reflections: Hypoxia-Induced PLOD2 Is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
Okumura Y; Eguchi H
Ann Surg Oncol; 2018 Nov; 25(12):3738-3739. PubMed ID: 30167909
[No Abstract] [Full Text] [Related]
6. ASO Author Reflections: Routine Radiologic Staging of Distant Metastases Must Be Recommended as a Binding Guideline After Diagnosis of Local Breast Cancer Recurrence.
Güth U
Ann Surg Oncol; 2019 Oct; 26(11):3462-3463. PubMed ID: 31313032
[No Abstract] [Full Text] [Related]
7. Adjuvant Therapy for Biliary Tract Cancers.
Horgan AM; Knox JJ
J Oncol Pract; 2018 Dec; 14(12):701-708. PubMed ID: 30537458
[TBL] [Abstract][Full Text] [Related]
8. ASO Author Reflections: Characteristics of Surgery for Biliary Tract Cancer that Should be Considered During the Design of Future Clinical Trials.
Kobayashi S; Ikeda M; Nakachi K; Ueno M; Okusaka T; Todaka A; Satoi S; Tomokuni A; Konishi M; Furuse J
Ann Surg Oncol; 2023 Nov; 30(12):7384-7385. PubMed ID: 37442909
[No Abstract] [Full Text] [Related]
9. ASO Author Reflections: Adjuvant Chemoradiation for Patients with Resected Biliary Tract Cancers.
Dee EC; Freret ME; Wo JY
Ann Surg Oncol; 2020 Dec; 27(13):5173-5174. PubMed ID: 32748150
[No Abstract] [Full Text] [Related]
10. ASO Author Reflections: Clinical Implication of Nomograms in the Breast Oncology Field.
Corso G
Ann Surg Oncol; 2020 Jun; 27(6):1875-1876. PubMed ID: 32103418
[No Abstract] [Full Text] [Related]
11. ASO Author Reflections: Effectiveness of Resection of Oligometastases from Esophageal Cancer.
Ohkura Y
Ann Surg Oncol; 2020 Mar; 27(3):660-661. PubMed ID: 31907746
[No Abstract] [Full Text] [Related]
12. [Analysis of mode of cancer recurrence].
Suzuki T
Nihon Geka Hokan; 1989 Jul; 58(4):345-6. PubMed ID: 2634364
[No Abstract] [Full Text] [Related]
13. ASO Author Reflections: The Strengths and Weaknesses of Intraoperative Radiotherapy for Early Breast Cancer and Ipsilateral Tumor Recurrence.
Sawaki M; Kodaira T; Iwata H
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):660-661. PubMed ID: 31359282
[No Abstract] [Full Text] [Related]
14. ASO Author Reflections: Phase II Trial of Adjuvant Chemotherapy with S-1 for Node-Positive Biliary Tract Cancer (N-SOG 09).
Ebata T; Mizuno T
Ann Surg Oncol; 2020 Jul; 27(7):2357-2358. PubMed ID: 32206952
[No Abstract] [Full Text] [Related]
15. Outcomes in biliary malignancy.
Groot Koerkamp B; Fong Y
J Surg Oncol; 2014 Oct; 110(5):585-91. PubMed ID: 25250887
[TBL] [Abstract][Full Text] [Related]
16. ASO Author Reflections: Prognostic Impact of Budding Grade on Patients with Residual Liver Recurrence of Colorectal Cancer After Initial Hepatectomy.
Noro T
Ann Surg Oncol; 2020 Dec; 27(13):5208. PubMed ID: 32770295
[No Abstract] [Full Text] [Related]
17. ASO Author Reflections: Adjuvant Chemotherapy for Resected Biliary Tract Cancers-Does One Size Fit All?
Rhodin KE; Lidsky ME
Ann Surg Oncol; 2023 Aug; 30(8):4822-4823. PubMed ID: 37149546
[No Abstract] [Full Text] [Related]
18. Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials.
Belkouz A; Wilmink JW; Haj Mohammad N; Hagendoorn J; de Vos-Geelen J; Dejong CHC; Homs MYV; Groot Koerkamp B; van Gulik TM; van Oijen MGH; Punt CJA; Klümpen H
Crit Rev Oncol Hematol; 2020 Jul; 151():102975. PubMed ID: 32464483
[TBL] [Abstract][Full Text] [Related]
19. ASO Author Reflections: Can We Predict an Unsalvageable Recurrence Following Colorectal Liver Metastasectomy?
Okuno M; Conrad C
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):549-550. PubMed ID: 30565037
[No Abstract] [Full Text] [Related]
20. ASO Author Reflections: Revisiting Risk of Dissemination from Small Rectal Neuroendocrine Tumors.
Folkert IW; Roses RE
Ann Surg Oncol; 2020 Mar; 27(3):864-865. PubMed ID: 31749081
[No Abstract] [Full Text] [Related]
[Next] [New Search]
